Key Insights

Highlights

Success Rate

75% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

15.0%

3 terminated out of 20 trials

Success Rate

75.0%

-11.5% vs benchmark

Late-Stage Pipeline

15%

3 trials in Phase 3/4

Results Transparency

78%

7 of 9 completed with results

Key Signals

7 with results75% success

Data Visualizations

Phase Distribution

18Total
Not Applicable (1)
P 1 (13)
P 2 (1)
P 3 (2)
P 4 (1)

Trial Status

Completed9
Unknown5
Terminated3
Recruiting2
Active Not Recruiting1

Trial Success Rate

75.0%

Benchmark: 86.5%

Based on 9 completed trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT02879643Phase 1Completed

Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy

NCT05440409Completed

CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALL

NCT03817320Phase 1Active Not Recruiting

PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

NCT01186328Phase 1Terminated

EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

NCT01614197Phase 1CompletedPrimary

A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

NCT05429905Phase 1Unknown

Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia

NCT05495035Phase 1UnknownPrimary

Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL

NCT05611086Phase 4TerminatedPrimary

N-Acetylcysteine vs Placebo as Adjunctive Treatment in Pediatric Leukemia

NCT01411267Phase 1CompletedPrimary

AC220 for Children With Relapsed/Refractory ALL or AML

NCT05043571Phase 1RecruitingPrimary

CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia

NCT05038696Phase 1RecruitingPrimary

ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.

NCT02906371Phase 1CompletedPrimary

Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome

NCT01861002Phase 1CompletedPrimary

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

NCT03022747Phase 2UnknownPrimary

Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol

NCT01321346Phase 1CompletedPrimary

A Study Of Panobinostat In Children With Refractory Hematologic Malignancies

NCT01423747Phase 3UnknownPrimary

Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia

NCT01423500Phase 3UnknownPrimary

ALL-SCT BFM International- HSCT in Children and Adolescents With ALL

NCT00991133Phase 1CompletedPrimary

A Safety and Tolerability Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Acute Lymphoblastic Leukemia (ALL)

NCT01100658Not ApplicableTerminated

Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors

NCT01896752CompletedPrimary

Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL

Showing all 20 trials

Research Network

Activity Timeline